Evogene Ltd. (EVGN)Healthcare | Biotechnology | Rehovot, Israel | NasdaqCM
0.55 USD
+0.01
(2.156%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 0.55 |
Hot Take ↕ | Aug. 22, 2026, 5:46 a.m. EDT
The investment case for this biotech stock is currently broken by a catastrophic multi-year decline and deteriorating fundamentals. Over the last nine years, the share price has collapsed by approximately 98%, with the most recent four years showing consecutive annual losses. This sustained downward trajectory, combined with negative revenue growth of nearly 86% and significant operating losses, indicates a business that is failing to execute or sustain its operations. While the company recently announced a successful Phase 1 clinical study, which offers a potential catalyst for future recovery, the current financial reality—characterized by shrinking revenues, negative free cash flow, and a lack of analyst coverage—makes it a poor candidate for immediate capital allocation. There is no dividend to provide income, and the balance sheet shows signs of stress with negative book value and high debt relative to equity. The recent price action remains volatile and depressed, trading well below key moving averages, suggesting that even the latest clinical success has not yet stabilized investor sentiment. Until there is clear evidence of revenue stabilization and a path to profitability, the risk of further capital erosion outweighs the speculative upside. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.225967 |
| AutoTheta | 0.238531 |
| AutoETS | 0.297635 |
| MSTL | 0.300874 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 0.77 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.605 |
| Excess Kurtosis | -0.38 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 36.425 |
| Revenue per Share | 0.165 |
| Market Cap | 8,684,453 |
| Forward P/E | -0.69 |
| Beta | 0.68 |
| Website | https://www.evogene.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.5609756 |
| Address1 | 13 Gad Feinstein Street |
| Address2 | Park Rehovot |
| All Time High | 203.9 |
| All Time Low | 0.37 |
| Ask | 0.7061 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 272,110 |
| Average Daily Volume3 Month | 1,912,125 |
| Average Volume | 1,912,125 |
| Average Volume10Days | 272,110 |
| Beta | 0.683 |
| Bid | 0.378 |
| Bid Size | 2 |
| Book Value | -0.243 |
| City | Rehovot |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.5496 |
| Current Ratio | 3.566 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 0.5599 |
| Day Low | 0.5426 |
| Debt To Equity | 36.425 |
| Display Name | Evogene |
| Earnings Call Timestamp End | 1,787,058,000 |
| Earnings Call Timestamp Start | 1,787,058,000 |
| Earnings Timestamp | 1,787,056,200 |
| Earnings Timestamp End | 1,795,091,400 |
| Earnings Timestamp Start | 1,795,091,400 |
| Ebitda | -13,971,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.664 |
| Enterprise To Revenue | 5.602 |
| Enterprise Value | 9,282,299 |
| Eps Current Year | -1.7 |
| Eps Forward | -0.8 |
| Eps Trailing Twelve Months | -1.78 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 972 8 946 6724 |
| Fifty Day Average | 0.5312 |
| Fifty Day Average Change | 0.018400013 |
| Fifty Day Average Change Percent | 0.03463858 |
| Fifty Two Week Change Percent | -56.09756 |
| Fifty Two Week High | 1.5 |
| Fifty Two Week High Change | -0.9504 |
| Fifty Two Week High Change Percent | -0.6336 |
| Fifty Two Week Low | 0.37 |
| Fifty Two Week Low Change | 0.1796 |
| Fifty Two Week Low Change Percent | 0.4854054 |
| Fifty Two Week Range | 0.37 - 1.5 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,287,149,400,000 |
| Float Shares | 12,192,005 |
| Forward Eps | -0.8 |
| Forward P E | -0.687 |
| Free Cashflow | -2,041,250 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 38 |
| Fullday Change | 0.0116 |
| Fullday Change Percent | 2.15614 |
| Fullday Price | 0.549 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | -0.67592 |
| Gross Profits | -1,120,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.27861 |
| Held Percent Institutions | 0.06364 |
| Implied Shares Outstanding | 15,801,407 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,721,865,600 |
| Last Split Factor | 1:10 |
| Long Business Summary | Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD); and with ELEO, Inc. to develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. The company was incorporated in 1999 and is headquartered in Rehovot, Israel. |
| Long Name | Evogene Ltd. |
| Market | us_market |
| Market Cap | 8,684,453 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_3274115 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -17,832,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 8,632,851 |
| Number Of Analyst Opinions | 1 |
| Open | 0.5566 |
| Operating Cashflow | -10,947,000 |
| Operating Margins | -7.38617 |
| Payout Ratio | 0.0 |
| Phone | 972 8 931 1900 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 0.549 |
| Post Market Time | 1,787,947,804 |
| Previous Close | 0.538 |
| Price Eps Current Year | -0.3232941 |
| Price Hint | 4 |
| Price To Book | -2.2617285 |
| Price To Sales Trailing12 Months | 5.24107 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.524 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.011600018 |
| Regular Market Change Percent | 2.1561372 |
| Regular Market Day High | 0.5599 |
| Regular Market Day Low | 0.5426 |
| Regular Market Day Range | 0.5426 - 0.5599 |
| Regular Market Open | 0.5566 |
| Regular Market Previous Close | 0.538 |
| Regular Market Price | 0.5496 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 15,030 |
| Return On Assets | -0.37796003 |
| Return On Equity | -1.82748 |
| Revenue Growth | -0.607 |
| Revenue Per Share | 0.165 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 15,801,407 |
| Shares Percent Shares Out | 0.0147 |
| Shares Short | 232,078 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 248,770 |
| Short Name | Evogene Ltd. |
| Short Percent Of Float | 0.0148 |
| Short Ratio | 0.39 |
| Source Interval | 15 |
| Symbol | EVGN |
| Target High Price | 2.15 |
| Target Low Price | 2.15 |
| Target Mean Price | 2.15 |
| Target Median Price | 2.15 |
| Total Cash | 9,316,000 |
| Total Cash Per Share | 0.688 |
| Total Debt | 2,101,000 |
| Total Revenue | 1,657,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.78 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.8121 |
| Two Hundred Day Average Change | -0.2625 |
| Two Hundred Day Average Change Percent | -0.32323605 |
| Type Disp | Equity |
| Volume | 15,030 |
| Website | https://www.evogene.com |
| Zip | 7,638,517 |